Versanis Bio
Oakland
About Versanis Bio
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults. Versanis Bio is advancing Bimagrumab, a human monoclonal antibody to the activin type II receptors that block the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies, Bimagrumab treatment consistently and potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $70.0M
- Funding stage: M&A
- Last round: Series A (Aug 2021)
- Website: versanisbio.com
- Phone: (617) 315-4410
Industries & Categories
Biotechnology, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/versanis-bio-53255 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.